Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aptose Biosciences, Inc. - Common Shares (TSX:APS)

1.850 +0.170 (+10.12%)
Streaming Delayed Price Updated: 12:03 PM EDT, Oct 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aptose Biosciences, Inc. - Common Shares

< Previous 1 2 3 Next >
Aptose’s Tuspetinib Exceeds Expectations When Combined with Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML
Data from Phase 1/2 TUSCANY trial presented at the European School of Haematology (ESH) 7th International Conference 
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose and Hanmi Pharmaceutical Extend Loan Agreement to Continue Development of Tuspetinib in Triplet Therapy for AML
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Biosciences Announces Results of Reconvened Annual and Special Shareholders Meeting and Appointment of Ernst & Young LLP as New Auditor
Aptose also Receives Additional Advance from Hanmi Pharmaceutical to Continue Development of Tuspetinib in Triplet Therapy for AML 
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Reports Early Data Demonstrating Tuspetinib Improves Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML in Phase 1/2 TUSCANY Trial
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Reports Second Quarter 2025 Results
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Enrollment is Open for 160 mg Dosing Cohort of Tuspetinib in Phase 1/2 TUSCANY Trial of Frontline Triple Drug Therapy
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Selects Ernst & Young Global Limited as its New Independent Auditor and Calls Reconvened Meeting of its Shareholders
Aptose to hold a reconvened shareholder meeting on August 22, 2025 at 10:00 a.m. (Eastern Time) to vote on appointment of new auditor 
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Receives Second Advance under the Loan Agreement with Hanmi Pharmaceutical to Continue Development of Tuspetinib in Triplet Therapy for AML
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Upgraded to Trade on OTCQB Market
Aptose will trade under the ticker symbol APTOF and begin trading on OTCQB today, July 1st 
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Announces Deferral of Interest Payment
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose and Hanmi Enter New Loan Agreement to Advance Development of Tuspetinib in Triplet Therapy for AML
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Provides Corporate Updates
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2025 EHA Congress
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Announces Results from Annual and Special Meeting of Shareholders
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Announces Dosing of First Patient with 120 mg of Tuspetinib in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy after Dose Escalation Decision by Safety Review Committee
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Selected for Prestigious Oral Presentation of Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2025 EHA Congress
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Reports First Quarter 2025 Results
Highlights Progress in TUSCANY Clinical Trial of Tuspetinib in AML Triple Frontline Therapy 
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Provides Clinical Update for the Tuspetinib-based Triple Drug Frontline Therapy in Newly Diagnosed AML Patients from the Phase 1/2 TUSCANY Trial
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Announces Auditor Not Standing for Re-Appointment
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Common Shares to Delist from Nasdaq as of April 2, 2025
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Reports Year End 2024 Results and Corporate Highlights
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Announces Positive Clinical Safety Review Committee (CSRC) Approval to Dose Escalate in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy with Tuspetinib Amid Complete Responses and Favorable Safety in First Cohort
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Announces Reverse Share Split
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Enters into $25 Million Committed Equity Facility and Establishes New At-The-Market Facility
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose’s Frontline Triple Drug Therapy with Tuspetinib Achieves Notable Responses in Newly Diagnosed AML Patients in the Phase 1/2 TUSCANY Trial
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Announces First AML Patients Dosed with Tuspetinib Triplet Frontline Therapy in TUSCANY Trial
TUS+VEN+AZA triplet has potential as frontline therapy to treat large, mutationally diverse populations of AML 
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Announces Positive Decision by Nasdaq Hearings Panel
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Announces Publication of Preclinical Data in AACR Journal Demonstrating Tuspetinib’s Unique Mechanism of Action and Synthetic Lethality on AML Cells When Combined with Venetoclax
From Aptose Biosciences, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.